Hybrid Closed Loop Systems: What the Evidence Shows About Automated Insulin Delivery

Hybrid closed loop (HCL) systems combine an insulin pump with continuous glucose monitoring to automatically adjust insulin delivery. Unlike older pump systems that require constant manual input, these newer devices use algorithms to make real-time decisions about how much insulin to give based on glucose readings.

Several HCL systems are now available, including Omnipod 5, Minimed 780G, Minimed 670G, and Control-IQ, among others. Each system works slightly differently, but they all aim to reduce the daily burden of diabetes management while improving glucose control.

A comprehensive analysis of 28 randomized clinical trials found that all HCL systems significantly increased time in target range (70–180 mg/dL) compared to traditional subcutaneous insulin therapy without continuous glucose monitoring. This is important because spending more time in range reduces the risk of both high and low blood sugar complications over time.

The systems did not perform identically. Minimed 780G achieved the highest time in range, followed by Control-IQ, Minimed 670G, and others. However, all systems successfully reduced time spent below target range, meaning fewer dangerous low blood sugar episodes. Importantly, the risk of severe hypoglycemia and diabetic ketoacidosis remained similar to other insulin therapies.

Clinical trials provide important evidence, but real-world data shows how these systems actually perform outside controlled study conditions. Research on nearly 70,000 Omnipod 5 users in the United States revealed a median time in range of about 69% for users targeting a glucose level of 110 mg/dL. Users targeting higher glucose levels (120–150 mg/dL) had lower time in range, but also minimal time spent below 70 mg/dL.

When researchers looked at all commercially available automated insulin delivery systems together, they found time in range varied from about 60% to 74% depending on the specific system. Importantly, younger users—children and adolescents—showed less favorable outcomes than adults, suggesting that age is an important factor in how well these systems work for different people.

The evidence showing a hierarchy of effectiveness among different HCL systems can help people with Type 1 diabetes and their healthcare teams make informed choices. What works best depends on individual circumstances, preferences, and needs—there is no one-size-fits-all answer.

Ongoing research continues to expand our understanding of these systems. New studies are tracking the long-term safety and effectiveness of automated insulin delivery, including its impact on diabetes-related stress for both users and caregivers, and the cost-effectiveness of these technologies compared to other treatment approaches.

Origin: YouTube / WMAR-2 News (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.